Jentadueto Xr Tablet, Film Coated, Extended Release
Product Images NDC 0597-0275

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Jentadueto Xr (NDC 0597-0275). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Jentadueto 01

Chemical structure of linagliptin, the active ingredient in Jentadueto XR tablets. The diagram shows the molecular arrangement without atomic labels beyond the carbon rings and key functional groups.*

FDA Label Image

Jentadueto 02

Chemical structure of linagliptin as part of linagliptin and metformin hydrochloride. The diagram shows the molecular structure including nitrogen, carbon, and hydrogen atoms, along with a hydrochloride component indicated by ". HCl".*

FDA Label Image

Jentadueto 03

A line graph illustrating the adjusted mean percentage change in A1C levels from baseline over 24 weeks for different treatment groups, including Placebo, Linagliptin 5 mg once daily, Metformin 500 mg twice daily, Linagliptin 2.5 mg plus Metformin 500 mg twice daily, Metformin 1000 mg twice daily, and Linagliptin 2.5 mg plus Metformin 1000 mg twice daily. The graph shows week intervals on the x-axis and percentage change on the y-axis.*

FDA Label Image

Jentadueto 04

A line graph comparing the percentage of patients with an event over 3.5 years for linagliptin versus placebo. The x-axis shows years, and the y-axis shows patients with event (%). Both lines rise gradually with similar trends. Below the graph, a table lists patient risk counts for placebo and linagliptin groups at various time points.*

FDA Label Image

Jentadueto 05

A line graph comparing the percentage of patients with an event over time, measured in years, for the drugs linagliptin and glimepiride. The x-axis represents years (0 to 7), and the y-axis shows the percentage of patients with the event (0% to 16%). Two lines show event rates for each drug with patient counts at risk listed below the x-axis for each year.*

FDA Label Image

Jentadueto 06

FDA Label Image

Jentadueto 07

Jentadueto XR 2.5 mg/1000 mg extended-release film-coated tablets, containing linagliptin and metformin hydrochloride, in a 60-tablet prescription package. The label includes dosage strength, storage instructions, dispensing requirements, manufacturer Boehringer Ingelheim Pharmaceuticals, Inc., and barcode.*

FDA Label Image

Jentadueto 08

Label for Jentadueto XR 5 mg/1000 mg film-coated extended-release tablets containing linagliptin and metformin hydrochloride. The label shows the product name, dosage strength, quantity of 30 tablets, and the Boehringer Ingelheim Pharmaceuticals, Inc. logo. Storage, dispensing, and safety instructions are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.